At present, ginkgo drugs used in clinic are mostly compound preparations with effective parts as the main components. With the definition of effective medicinal components in Ginkgo biloba leaves, new drugs with single effective components have become the object of development in France, Britain, Germany and the United States in recent years. The mixed preparation of ginkgolides A, B and C has entered the third phase of clinical research, which is used to treat asthma, and its curative effect on patients with septic shock, cerebral ischemia, kidney transplantation and burn is evaluated. Domestic preparations based on ginkgolide B are also under development.
This new preparation can further improve the curative effect, improve the safety of medication, control the quality of drugs more easily, and have more clinical application prospects. Especially in the treatment of cerebrovascular diseases, among the 57 countries surveyed by WHO, 1 1.3% people died of cerebrovascular diseases, among which 40 countries ranked among the top three causes of death. Large doses of drugs are often needed to treat emergencies, but the dose-effect relationship of some effective parts of natural drugs is not stable enough, which affects the clinical dose selection. Ginkgolide B is a fat-soluble substance, which can pass through the blood-brain barrier smoothly. Clinical experiments of ginkgolide B injection independently developed in China have preliminarily proved that it can treat ischemic encephalopathy including acute ischemic cerebral infarction, and it is expected to become a new choice for treating acute ischemic diseases.